|
|
FOR IMMEDIATE RELEASE
Contact: Ronald Trahan, APR, Ronald Trahan Associates Inc.
508-359-4005, x108
Pico-Tesla elects Dr. Francis Bellido as a director
LITTLETON, Colo., and CLEARWATER, Fla., May 10, 2010 — Pico-Tesla, the
Magneceutical® company, announced today that it has elected Francis Bellido, Ph.D., as its
first outside director, effective immediately.
Dr. Bellido has more than 25 years of international experience in the life sciences and finance
industries, holding several top executive positions in both small and large companies. Most
recently, he was President and Chief Operating Officer at Supratek
Pharma, a pharmaceutical company specializing in the
development of cancer drugs. Prior to Supratek Pharma, Dr. Bellido
was President and Chief Executive Officer of SGF-Santé, where he
managed a $500M health science investment portfolio. Earlier in
his career, Dr. Bellido held several executive positions with Eli
Lilly in the United States and Europe, including Strategic Asset
Director, Global Business Unit Manager, and Head of Regulatory
Affairs. He holds a master’s degree in pharmaceutical sciences and
a doctorate in medical microbiology from the University of Geneva
in Switzerland, and an MBA degree from the University of
Montréal. In addition, Dr. Bellido has held the position of Invited
Professor at the School of Management of the University of Québec
in Montréal.
“We are extremely pleased to announce the election of Dr. Bellido as the Company’s first outside
director,” said Allen Braswell, CEO of Pico-Tesla. “With his significant experience and
considerable achievements, Dr. Bellido will be an invaluable resource to Pico-Tesla as the
Company evolves its Magneceutical® therapies for Parkinson’s Disease and type 2 diabetes.”
The purpose of the Company’s ongoing Phase III clinical trial is to demonstrate the efficacy of
Magneceutical® Therapy as an adjunctive therapy to improving aspects of health and quality of
life that are relevant to patients with Parkinson's Disease. Pico-Tesla intends to submit the Phase
III data and analysis via a 510(k) de novo application to obtain FDA clearance to sell the device
in the United States. The Phase III clinical trial was designed by principal investigator Rajeev
Kumar, M.D., a movement disorder specialist and medical director of the Colorado
Neurological Institute Movement Disorder Center, Englewood, Colo.
Pico-Tesla also has been enrolling patients in a randomized, double-blinded, placebo-controlled
Pilot Study of persons who have type 2 diabetes, the most common form of diabetes. The Pilot
Study seeks to determine whether the application of magnetic fields generated by the Company’s
patented Resonator™ system can be effective as an adjunctive therapy to oral medications in
reducing hemoglobin A1c levels. The protocol for the Pilot Study was developed in consultation
with Michael McDermott, M.D., Director, Endocrinology and Diabetes Practice, University of
Colorado Health Science Center, Aurora, Colo.; and with Mitchell Gershten, M.D., an internist
and staff physician at Saint Mary’s Hospital in Grand Junction, Colo.
Pico-Tesla’s Magneceutical® Therapy involves the use of an extremely low-level
electromagnetic field (EMF) applied by a specially designed device—the Resonator™,
invented by Dr. Jerry I. Jacobson, along with proprietary therapeutic protocols—intended to improve a number of the
signs and symptoms of Parkinson’s and other diseases, including type 2 diabetes.
Privately held Pico-Tesla Magnetic Therapies is an emerging medical technology company with
operations at: 4700
140th Avenue North, Suite #101, Clearwater, FL 33762. Additionally, given that Pico-Tesla is
a Limited Liability Company, its Directors are formally known as “managers”, and the terms are
used interchangeably.
CAUTION: The Resonator™ device is an Investigational Device limited by federal (or United States) law
to investigational use. The Resonator™ device is not for sale, nor is the Magneceutical® Therapy generally
available outside of Investigational Review Board (IRB)-approved clinical studies.
|
